HPK1-IN-2

CAS No. 2056122-11-1

HPK1-IN-2( Thieno[2,3-b]pyridin-6(7H)-one, 4-amino-5-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-HPK1-IN-2 )

Catalog No. M23923 CAS No. 2056122-11-1

HPK1-IN-2 is a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1;IC50<0.05 μΜ).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 164 In Stock
5MG 139 In Stock
10MG 231 In Stock
25MG 386 In Stock
50MG 537 In Stock
100MG 714 In Stock
200MG 918 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    HPK1-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    HPK1-IN-2 is a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1;IC50<0.05 μΜ).
  • Description
    HPK1-IN-2 is a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1;IC50<0.05 μΜ). It also inhibits Lck (0.05 μΜ
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Thieno[2,3-b]pyridin-6(7H)-one, 4-amino-5-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-HPK1-IN-2
  • Pathway
    Angiogenesis
  • Target
    FLT
  • Recptor
    Flt3|HPK1|Lck
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2056122-11-1
  • Formula Weight
    380.47
  • Molecular Formula
    C19H20N6OS
  • Purity
    >98% (HPLC)
  • Solubility
    H2O:25 mg/mL?(55.14 mM;?Need ultrasonic)
  • SMILES
    O=C1C(C2=NC3=CC=C(N4CCN(C)CC4)C=C3N2)=C(N)C(C=CS5)=C5N1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Peter Brent Sampson, et al. Hpk1 inhibitors and methods of using same. WO2016205942A1.
molnova catalog
related products
  • FLT3-IN-3

    FLT3-IN-3 is an effective FLT3 inhibitor, and the IC50s of FLT3 WT and FLT3 D835Y are 13 and 8 nM, respectively.

  • FLT3-IN-10

    FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 shows the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).

  • JI6

    JI6 (JAK3 Inhibitor VI) is a potent, selective and orally active FLT3 inhibitor. JI6 exhibits IC50s of ~40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.